DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-15
DOI
10.1007/s15010-022-01904-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
- (2022) Jonaid Ahmad Malik et al. Journal of Infection and Public Health
- An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
- (2021) Álvaro Réa-Neto et al. Scientific Reports
- Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
- (2021) Roberto Caricchio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- (2020) Xiaobo Yang et al. Lancet Respiratory Medicine
- The Architecture of SARS-CoV-2 Transcriptome
- (2020) Dongwan Kim et al. CELL
- Association of inflammatory markers with the severity of COVID-19: a meta-analysis
- (2020) Furong Zeng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
- (2020) Chaomin Wu et al. JAMA Internal Medicine
- Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques
- (2020) Chao Shan et al. CELL RESEARCH
- COVID ‐19 acute respiratory distress syndrome ( ARDS ): clinical features and differences from typical pre‐ COVID ‐19 ARDS
- (2020) Peter G Gibson et al. MEDICAL JOURNAL OF AUSTRALIA
- The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
- (2020) Jana Knorr et al. SEMINARS IN LIVER DISEASE
- Targeting the NLRP3 Inflammasome in Severe COVID-19
- (2020) Tracey L. Freeman et al. Frontiers in Immunology
- Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis
- (2020) Xudong Feng et al. Frontiers in Medicine
- Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
- (2020) Adam G. Schwaid et al. JOURNAL OF MEDICINAL CHEMISTRY
- COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative review
- (2020) Carmen A. Pfortmueller et al. Best Practice & Research-Clinical Anaesthesiology
- Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease
- (2019) Md. Ezazul Haque et al. MOVEMENT DISORDERS
- NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis
- (2018) C Guo et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Interleukin-1β Causes Acute Lung Injury via αvβ5 and αvβ6 Integrin–Dependent Mechanisms
- (2008) Michael T. Ganter et al. CIRCULATION RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started